EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
By Weiya Zhang, M. Doherty, T. Bardin, E. Pascual, V. Barskova, Philip G. Conaghan, J. Gerster, J. Jacobs, B. Leeb, F. Lioté and 10 more. Annals of the Rheumatic Diseases, 2006
1,376 citations recorded by the source corpus.
Subfields: Complementary and alternative medicine, Endocrinology, Diabetes and Metabolism, Nephrology
View Paper: https://www.semanticscholar.org/paper/4bb04214b9bb22798d46a867a4f67481ba87b1d5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Nephrology
Citations in the corpus
- 2012 American College of Rheumatology Guidelines for Management of Gout Part II: Therapy and Anti-inflammatory Prophylaxis of Acute Gouty Arthritis (2012, background): “Prior EULAR and BSR recommendations on colchicine dosing for acute gout (10,12) and colchicine low-dose regimen pharmacokinetics (26) informed the TFP recommendation of low-dose colchicine (at a maximum of 0.6 mg twice daily) as a continuation option for an acute gout attack, if started at least 12 ”
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, positive): “The current European League Against Rheumatism (EULAR) guideline for the management of gout recommends that urate-lowering therapy (ULT) is indicated in patients with recurrent acute flares, arthropathy, tophi or radiographic changes of gout, aiming to maintain a serum urate level below the saturati”